Novartis, Amgen and the Banner Alzheimer’s Institute (BAI) have partnered for the new Alzheimer’s Prevention Initiative (API) Generation Study 2 trial.

The latest trial follows the launch of the Generation Study 1 and will determine whether the BACE1 inhibitor CNP520 can prevent or delay the onset of Alzheimer’s disease (AD) symptoms in a high-risk population.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

BACE1 enzyme plays a vital role in the production of Amyloid ß protein that accumulates in the brains of individuals with AD years before the start of clinical symptoms.

Novartis Drug Development global head and chief medical officer Vas Narasimhan said: “Expanding our collaboration with Banner Alzheimer’s Institute stands testament to our belief that preventing amyloid buildup is one of the most promising approaches to treating Alzheimer’s disease.

“Expanding our collaboration with Banner Alzheimer’s Institute stands testament to our belief that preventing amyloid buildup is one of the most promising approaches to treating Alzheimer’s disease.”

“If we determine that our BACE1 inhibitor can prevent or delay the onset of symptoms in healthy yet high-risk populations, this would represent a tremendous breakthrough for those that may face this debilitating disease.”

As part of the five-year Generation Study 2, enrolling of participants started in the US in August this year. The study will eventually include more than 180 sites in more than 20 countries worldwide.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

About 2,000 cognitively healthy participants aged 60 to 75, who are at high risk of developing AD based on their age and those carrying either two copies of the apolipoprotein E (APOE) 4 gene or one copy of the gene with evidence of elevated brain amyloid, will be recruited for the study.

Recruitment will be carried out through multiple venues, including the Alzheimer’s Prevention Registry’s GeneMatch programme.

Led by BAI, the API conducts prevention trials in cognitively healthy people at increased genetic risk for AD.